AU3173301A - Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity - Google Patents
Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activityInfo
- Publication number
- AU3173301A AU3173301A AU31733/01A AU3173301A AU3173301A AU 3173301 A AU3173301 A AU 3173301A AU 31733/01 A AU31733/01 A AU 31733/01A AU 3173301 A AU3173301 A AU 3173301A AU 3173301 A AU3173301 A AU 3173301A
- Authority
- AU
- Australia
- Prior art keywords
- plasmin
- alzheimer
- disease
- compositions
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000024827 Alzheimer disease Diseases 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 230000002708 enhancing effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 229940012957 plasmin Drugs 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/484—Plasmin (3.4.21.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50244800A | 2000-02-11 | 2000-02-11 | |
US09502448 | 2000-02-11 | ||
US71492800A | 2000-11-17 | 2000-11-17 | |
US09714928 | 2000-11-17 | ||
PCT/EP2001/001517 WO2001058476A2 (fr) | 2000-02-11 | 2001-02-12 | Procedes et compositions pour le traitement de la maladie d'alzheimer par le renforcement de l'activite de la plasmine ou de l'activite du type de la plasmine |
Publications (1)
Publication Number | Publication Date |
---|---|
AU3173301A true AU3173301A (en) | 2001-08-20 |
Family
ID=27054164
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU31733/01A Abandoned AU3173301A (en) | 2000-02-11 | 2001-02-12 | Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU3173301A (fr) |
WO (1) | WO2001058476A2 (fr) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030199463A1 (en) * | 2002-04-23 | 2003-10-23 | Silviu Itescu | DNA enzyme to inhibit plasminogen activator inhibitor-1 |
EP1380290A1 (fr) | 2002-07-09 | 2004-01-14 | Universitair Medisch Centrum Utrecht | La voie de la structure cross-béta et sa pertinence thérapeutique |
CA2499599A1 (fr) * | 2002-09-17 | 2004-04-01 | New York University | Procedes pour traiter les alterations de la memoire liees a l'age (aami), les deficits cognitifs legers (mci) et les demences au moyen d'inhibiteurs du cycle cellulaire |
US8114832B2 (en) | 2005-07-13 | 2012-02-14 | Crossbeta Biosciences B.V. | Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition |
CA2615028A1 (fr) | 2005-07-13 | 2007-01-18 | Crossbeta Biosciences B.V. | Composes de liaison de structures .beta.-croisees |
AU2007238608A1 (en) | 2006-04-14 | 2007-10-25 | Massachusetts Institute Of Technology | Identifying and modulating molecular pathways that mediate nervous system plasticity |
EP2135607A1 (fr) | 2008-06-18 | 2009-12-23 | Pharnext | Combinaison de pilocarpine et methimazol pour le traitement de la maladie de Charcot-MarieTooth et des troubles associés |
EP2323687A2 (fr) * | 2008-09-11 | 2011-05-25 | H. Lundbeck A/S | Procédé de sur-régulation de sorla pour traiter la maladie d alzheimer |
EP2322163A1 (fr) | 2009-11-03 | 2011-05-18 | Pharnext | Nouvelles approches thérapeutiques pour traiter la maladie d'Alzheimer |
US9387206B2 (en) | 2009-11-03 | 2016-07-12 | Pharnext | Therapeutic approaches for treating Alzheimer's disease |
US9241933B2 (en) | 2011-03-01 | 2016-01-26 | Pharnext | Compositions for treating amyotrophic lateral sclerosis |
US10010515B2 (en) | 2011-03-01 | 2018-07-03 | Pharnext | Therapeutic approaches for treating Parkinson's disease |
ES2665569T3 (es) | 2011-03-01 | 2018-04-26 | Pharnext | Tratamiento de la isquemia cerebral |
US9248111B2 (en) | 2011-03-01 | 2016-02-02 | Pharnext | Therapeutic approaches for treating parkinson's disease |
US11938172B2 (en) * | 2017-06-19 | 2024-03-26 | Talengen International Limited | Method for regulating and controlling GLP-1/GLP-1R and drug |
TW201904990A (zh) * | 2017-06-23 | 2019-02-01 | 美商波麥堤克生物治療股份有限公司 | 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療 |
EP4118219A4 (fr) * | 2020-03-11 | 2024-04-17 | Shanghai Belief-Delivery Biomed Co., Ltd. | Nouvelle utilisation d'un composé d'aspirine pour augmenter l'expression d'acides nucléiques |
KR20220156927A (ko) * | 2020-03-24 | 2022-11-28 | 탈렌젠 인터내셔널 리미티드 | 알츠하이머병의 치료 방법 및 약물 |
WO2021190562A1 (fr) * | 2020-03-24 | 2021-09-30 | 泰伦基国际有限公司 | Méthode et médicament pour favoriser la dégradation d'une protéine mal repliée et d'un agrégat de celle-ci |
WO2022105788A1 (fr) * | 2020-11-17 | 2022-05-27 | 泰伦基国际有限公司 | Procédé et médicament pour augmenter le taux de bdnf |
WO2024094216A1 (fr) * | 2022-11-04 | 2024-05-10 | 泰伦基国际有限公司 | Procédé et médicament pour favoriser l'élimination de protéines pathologiques par système protéasome-ubiquitine et système lysosomal autophagique |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5520912A (en) * | 1993-07-02 | 1996-05-28 | Immuno Aktiengesellschaft | Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen |
US5589154A (en) * | 1994-11-22 | 1996-12-31 | Rutgers, The State University Of New Jersey | Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease |
DE19641180A1 (de) * | 1996-09-24 | 1998-03-26 | Schering Ag | Verfahren zur Darstellung von APP-Sekretase Modulation und deren Verwendung als Mittel zur Behandlung der Alzheimer'schen Erkrankung |
-
2001
- 2001-02-12 AU AU31733/01A patent/AU3173301A/en not_active Abandoned
- 2001-02-12 WO PCT/EP2001/001517 patent/WO2001058476A2/fr active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2001058476A2 (fr) | 2001-08-16 |
WO2001058476A3 (fr) | 2002-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU3173301A (en) | Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity | |
AU2001249835A1 (en) | Diagnosis and treatment of alzheimer's disease | |
EP1392287B8 (fr) | Usage de dérivés de l'azétidinone pour le traitement de la maladie d' Alzheimer. | |
HU0303037D0 (en) | Compounds to treat alzheimer's disease and pharmaceutical compositions containing them | |
AU2001233299A1 (en) | Methods for treating alzheimer's disease | |
AU2001273132A1 (en) | Compounds to treat alzheimer's disease | |
AU2002306848A1 (en) | Methods of treating alzheimer's disease with piperidin derivates | |
AU2002335794A1 (en) | Allylamides useful in the treatment of alzheimer's disease | |
AU2003231252A1 (en) | Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease | |
AU2002315131A1 (en) | Aminediols as agents for the treatment of alzheimer's disease | |
AU2001236592A1 (en) | Methods for diagnosis of alzheimer's disease | |
AU2002212471A1 (en) | Peptides for use in the treatment of alzheimer's disease | |
HUP0302718A3 (en) | Methods and compositions for the treatment of diseases of the eye | |
AU2002222108A1 (en) | Diagnosis and treatment of alzheimer's disease | |
AU2003248660A1 (en) | Treatment of vascular dysfunction and alzheimer's disease | |
AU5550800A (en) | Diagnosis and treatment of alzheimer's disease | |
AU2002312667A1 (en) | Individualization of therapy with alzheimer's disease agents | |
PL377110A1 (pl) | Zapobieganie i leczenie choroby Alzheimera | |
AU2003230848A1 (en) | Methods and compositions for treating alzheimer's disease | |
HUP0103149A3 (en) | Pharmaceutical composition for treatment of alzheimer's disease | |
AU2002232433A1 (en) | Methods and compositions for diagnosis and treatment of cancer using arginine m ethyltransferase 3 | |
AU2003223330A1 (en) | Compositions and method of treating alzheimer's disease | |
AU2001255439A1 (en) | Method of treating alzheimer's disease | |
AU2002303988A1 (en) | Methods of treating alzheimer's disease | |
AU2002346015A1 (en) | Beta-hydroxyamine derivatives useful in treatment of alzheimer's disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |